In vivo 基因编辑疗法治疗杂合子家族性高胆固醇血症:一项 I 期临床试验勘误
Author Correction: In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial
修正了 I 期临床试验中关于患者基线 apoB 和 apoA1 值的错误,这些错误源于单位转换时的排版错误。修正后的数据不影响试验的结论、患者资格、治疗效果评估及其他研究结果。
- Author Correction
- Published: 03 November 2026
- Ping Wan ORCID: orcid.org/0000-0003-2884-62701,2 na1,
- Siyuan Tang1 na1,
- Dongni Lin ORCID: orcid.org/0000-0002-2469-804X1 na1,
- Yuming Lu ORCID: orcid.org/0000-0002-0183-55743,4 na1,
- Mei Long1 na1,
- Ling Xiao3,
- Yanhong Jiang1,
- Jiaoyang Liao ORCID: orcid.org/0000-0002-0443-563X5,
- Xiaoying Ma3,
- Ying Liu3,
- Wensu Yu3,
- Michael Ott ORCID: orcid.org/0000-0002-1245-358X6,
- Zi Jun Wang ORCID: orcid.org/0000-0001-8977-43173 na2,
- Yuxuan Wu ORCID: orcid.org/0000-0002-9155-98833,5 na2,
- Taihua Yang ORCID: orcid.org/0000-0001-6767-50271,2 na2 &
- …
- Qiang Xia ORCID: orcid.org/0000-0001-9482-69511,2,7,8 na2
Nature Medicine (2026) Cite this article
Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04254-4, published online 3 March 2026.
In the original version of this article, Table 1 contained errors in the baseline apolipoprotein B (ApoB) and apolipoprotein A1 (ApoA1) values. These errors resulted from a transcription error during unit conversion from g/L to mg/dL, in which the ApoB and ApoA1 rows were inadvertently misaligned with the adjacent HDL-C and non-HDL-C rows, respectively. The corrected ApoB values are 164, 165, 119, 115, 104 and 171 mg/dL for Patients 1–6, respectively. The corrected ApoA1 values are 159, 174, 117, 157, 140 and 192 mg/dL for Patients 1–6, respectively. Table 1 has been corrected accordingly.
In the originally published Extended Data Fig. 2d, the values displayed represented the A-to-G frequencies measured in the treated samples before subtraction of the corresponding matched untreated-control background, whereas the figure legend described background-corrected values. Extended Data Fig. 2d has therefore been corrected to present the background-corrected net A-to-G editing values, and the corresponding source data have been updated accordingly.
These corrections do not alter the underlying sequencing data or the conclusions of the off-target assessment, nor do they affect patient eligibility, trial conduct, dose assignment, treatment administration, statistical analyses, safety or efficacy assessments, results, conclusions, or interpretation of the article.
Author information
Author notes
These authors contributed equally: Ping Wan, Siyuan Tang, Dongni Lin, Yuming Lu, Mei Long.
These authors jointly supervised this work: Zi Jun Wang, Yuxuan Wu, Taihua Yang, Qiang Xia.
Authors and Affiliations
Department of Liver Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Ping Wan, Siyuan Tang, Dongni Lin, Mei Long, Yanhong Jiang, Taihua Yang & Qiang Xia
Shanghai Key Laboratory of Precision Gene Editing and Clinical Translation, Shanghai, China
Ping Wan, Taihua Yang & Qiang Xia
YolTech Therapeutics, Shanghai, China
Yuming Lu, Ling Xiao, Xiaoying Ma, Ying Liu, Wensu Yu, Zi Jun Wang & Yuxuan Wu
School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China
Yuming Lu
Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
Jiaoyang Liao & Yuxuan Wu
Department of Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany
Michael Ott
Shanghai Institute of Transplantation, Shanghai, China
Qiang Xia
Shanghai Engineering Research Center of Transplantation and Immunology, Shanghai, China
Qiang Xia
Authors
- Ping Wan
- Siyuan Tang
- Dongni Lin
- Yuming Lu
- Mei Long
- Ling Xiao
- Yanhong Jiang
- Jiaoyang Liao
- Xiaoying Ma
- Ying Liu
- Wensu Yu
- Michael Ott
- Zi Jun Wang
- Yuxuan Wu
- Taihua Yang
- Qiang Xia
Corresponding authors
Correspondence to Zi Jun Wang, Yuxuan Wu, Taihua Yang or Qiang Xia.
About this article
Cite this article
Wan, P., Tang, S., Lin, D. et al. Author Correction: In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial. Nat Med (2026). https://doi.org/10.1038/s41591-026-04786-9
Published: 03 November 2026
Version of record: 03 November 2026
DOI: https://doi.org/10.1038/s41591-026-04786-9
来源:Nature Medicine · nature.com